Zyclara (imiquimod) / Mochida, Viatris, Bausch Health - LARVOL DELTA

Assessment of the therapeutic efficacy of rutin-loaded PLGA nanocapsule-based gel against imiquimod-induced psoriasis model using box-behnken design for optimization. (PubMed, Int J Pharm) - "Moreover, enzyme-linked immunosorbent assay (ELISA) results revealed that RT-NG4 treatment reduced the levels of TNF-α, IFN-ɣ, and IL-6 and inhibited antioxidative stress compared to pure RT gel. In conclusion, the novel RT-NG formulation demonstrated promising potential as an effective topical treatment for psoriasis, leveraging the therapeutic benefits of a natural product."

Journal • Dermatology • Immunology • Inflammation • Psoriasis • IL6 • TNFA

Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis in mice: effects alone and in combination with methotrexate. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "In conclusion, this study provides the first preclinical evidence that HMC, particularly in combination with MTX, ameliorates IMQ-induced psoriasis via modulation of inflammatory cytokines, oxidative stress, and histopathological damage. These findings suggest its potential as a therapeutic candidate that warrants further preclinical and clinical investigation in plaque-type psoriasis."

Journal • Preclinical • Dermatology • Immunology • Oncology • Psoriasis • IL17A • TNFA

Therapeutic mechanism of Pithecellobium clypearia Benth. on imiquimod-induced psoriasis revealed by tissue transcriptomics in mice. (PubMed, PLoS One) - "P. clypearia may ameliorate inflammation in psoriasis mice by modulating genes such as Hspa1a, Hspa1b, mt-Nd4l, mt-Nd5, mt-Nd6, Bcl2, Asns, Trib3, and associated pathways related to energy metabolism, cell growth, and apoptosis. Our study explored the underlying molecular mechanisms at the transcriptome level and provided a theoretical basis for further investigation into the efficacy of P. clypearia."

Journal • Preclinical • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Otorhinolaryngology • Psoriasis • Respiratory Diseases • BCL2 • CHAC1 • GZMA • HSPA1A • SLC7A5 • TRIB3

Enhanced clinical and systemic response with combination radiation therapy and topical imiquimod in mycosis fungoides: A pilot study (ASH 2025) - "Preliminary results from this pilot study indicate that topical IMQ combined with RT isgenerally safe and efficacious for MF, demonstrating significant clinical and histological responses,including evidence of an abscopal effect. Ongoing analyses will further investigate associated proteomic,transcriptomic, and metagenomic changes to enhance our understanding of the underlying immunologicmechanisms."

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Pruritus • T Cell Non-Hodgkin Lymphoma

SG05 The use of oral methotrexate in a case of Ferguson-Smith syndrome. (PubMed, Br J Dermatol) - "Despite 3 years of acitretin therapy, surgical excisions, imiquimod and repeated cryotherapy, the lesions remained poorly controlled. This case, along with her sister's experience, highlights oral methotrexate as a potential therapeutic option for refractory cases. Further studies are needed to explore its role in the management of this challenging condition."

Journal • Brain Cancer • Dermatology • Immunology • Inflammatory Arthritis • Neuralgia • Oncology • Ophthalmology • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Solid Tumor • TGFBR1

BI20 Treatment of refractory warts in idiopathic CD4 lymphopenia with pulsed-dye laser therapy. (PubMed, Br J Dermatol) - "A course of unlicensed therapeutic human papillomavirus vaccination and topical imiquimod for 6 months was attempted, without benefit...PDL remains unlicensed in the UK for treatment of warts and is not widely available. We report this case with the objective of highlighting (i) the potential value of this treatment for refractory warts in immunocompromised individuals and (ii) the need for clinical trials to assess its efficacy in immunocompromised cohorts."

Journal • Cardiovascular • Dermatology • Gastroenterology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Oncology • Sarcoidosis • CD4

DP04 A case of elastosis perforans serpiginosa in a patient with trisomy 21. (PubMed, Br J Dermatol) - "Regular medications were notable for tofacitinib to treat her psoriatic arthritis, moderately potent topical steroid preparations, and coal tar shampoo to treat her scalp psoriasis...Noted associations with EPS include connective tissue diseases such as cutis laxa, pseudoxanthoma elasticum, Ehlers-Danlos syndrome (EDS), Marfan syndrome and systemic sclerosis; trisomy 21; Rothmund-Thompson syndrome; and medications such as D-penicillamine...Reported treatments include topical corticosteroids, topical retinoids, cryotherapy, topical imiquimod, narrowband ultraviolet B radiation, oral isotretinoin and ablative carbon dioxide laser, with variable results. This case highlights that EPS should be considered in patients with trisomy 21 given the association. It also highlights that when undertaking a biopsy in suspected EPS it is important to take samples from the keratotic papules to ensure diagnostic accuracy."

Journal • Dermatology • Dermatopathology • Genetic Disorders • Hurler Syndrome • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rare Diseases • Rheumatology • Scleroderma • Seronegative Spondyloarthropathies • Systemic Sclerosis

Psoriasis intervention by Huai'er (): unveiling novel targetsnetwork pharmacology. (PubMed, J Tradit Chin Med) - "This study demonstrates that Huai'er (Trametes) exerts therapeutic effects on psoriasis by modulating STAT1, thereby inhibiting keratinocyte proliferation and inflammatory responses. The findings provide a foundation for further research into the potential of Huai'er (Trametes) as a treatment for psoriasis."

Journal • Dermatology • Immunology • Inflammation • Oncology • Psoriasis • IL17A • STAT1 • TNFA

Monitoring the effectiveness of noninvasive or minimally invasive therapies for nonmelanocytic lesions using reflectance confocal microscopy: a systematic review. (PubMed, Actas Dermosifiliogr) - "Evaluated therapies included ablative laser, cryosurgery, photodynamic therapy, 5-fluorouracil, imiquimod, and tirbanibulin, among others. RCM allows treatment optimization and early monitoring, even when inflammation hinders clinical assessment. It is recommended that RCM evaluations be performed starting at least 1 month after treatment for squamous conditions and 3 months for BCC."

Journal • Review • Actinic Keratosis • Basal Cell Carcinoma • Dermatology • Genetic Disorders • Non-melanoma Skin Cancer • Oncology • Rare Diseases • Skin Cancer • Squamous Cell Carcinoma

Light-emitting diode red light attenuates epidermal thickening and keratinocyte proliferation in psoriasis models. (PubMed, Sci Rep) - "In mouse models, a daily dose of 1280 J/cm2 decreased epidermal thickness when co-administered and administered following the development of a psoriasiform phenotype with imiquimod. These results suggest LED-RL may offer an efficacious and cost-effective alternative to existing therapies for mild to moderate psoriasis."

Journal • Dermatology • Immunology • Psoriasis • IL22

Effects of red light-emitting diode therapy in imiquimod-induced psoriasis in mice. (PubMed, J Photochem Photobiol B) - "In plasma, IL-22 was elevated in IMQ-treated animals but decreased in the IMQ + LED group (p < 0.05), while no significant changes were detected for IL-1β, IL-17A, IL-23, TNF-α, or macrophage inflammatory protein (MIP)-3α. Together, these results suggest that red LED phototherapy reduces clinical severity and partially modulates both local and systemic inflammation in IMQ-induced psoriasis, supporting its potential as a complementary therapeutic approach."

Journal • Preclinical • Dermatology • Immunology • Inflammation • Oncology • Psoriasis • IL17A • IL1B • IL22 • IL23A • TNFA

Comparative Efficacy of Photodynamic Therapy versus Conventional Therapies for Actinic Keratosis: A Systematic Review and Meta-Analysis. (PubMed, Photodiagnosis Photodyn Ther) - "While 5-fluorouracil monotherapy shows superior efficacy, PDT offers advantages for specific populations and Grade III lesions. Combination approaches optimize outcomes while maintaining PDT's favorable cosmetic and tolerability profile."

Journal • Retrospective data • Review • Actinic Keratosis • Dermatology • Transplantation

PEGylated Peptide for Targeted Inhibition of Human Antigen R as a Novel Therapeutic Strategy for Psoriasis: A Proof-of-Concept Study. (PubMed, Psoriasis (Auckl)) - "In this study, we report a peptide-based polymer to target HuR and evaluated their efficacy in treating imiquimod (IMQ)-induced psoriasis-like dermatitis in mice ears...The observed efficacy in mitigating key inflammatory markers (VEGF and IL-23) highlights the potential of this approach to offer superior specificity and reduced systemic side effects compared to current broad-spectrum immunosuppressants. This HuR-targeting strategy offers a potentially low-cost and effective therapeutic approach for psoriasis patients."

Journal • Cardiovascular • CNS Disorders • Dermatitis • Dermatology • Immunology • Inflammatory Arthritis • Mental Retardation • Metabolic Disorders • Psoriasis • Psychiatry • Rheumatology • IL23A

PapMV nanoparticles: A novel pathway to SARS-CoV-2 protection, distinct from Imidazoquinolines. (PubMed, Nanomedicine) - "To date, only imiquimod (IMQ) has received FDA approval, and its use is restricted to topical applications...Although the cellular responses to these two types of agonists differ strikingly, both are capable of eliciting antiviral immunity. We confirmed this potential for PapMV nano by demonstrating its capacity to prevent SARS-CoV-2 infection, supporting its utilization as a safe and effective immune modulator, capable of providing broad protection against respiratory viruses."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Identification and experimental validation of biomarkers associated with macrophages in myocardial ischemia-reperfusion injury. (PubMed, Sci Rep) - "Drug prediction and molecular docking analyses indicated that IMIQUIMOD and Acetaminophen might serve as potential therapeutic targets for MIRI...Notably, Tlr7 and Tlr1 were predominantly expressed in M2 macrophages. Tlr7, Tlr1, Tlr6, and Il33 were identified as macrophage-associated biomarkers in MIRI, providing valuable insights for MIRI diagnosis and potential therapeutic interventions."

Biomarker • Journal • Cardiovascular • Myocardial Ischemia • Reperfusion Injury • IL33 • MIR15A • TLR1 • TLR7

Resistance of endothelial cells to SARS-CoV-2 infection in vitro. (PubMed, J Virol) - "Each cultured endothelial cell type displayed functional viral responses by increased release of IP-10 when stimulated with Poly-IC (TLR3) or Imiquimod (TLR7/8)...Our findings are in line with the idea that vascular inflammation and thrombosis seen in COVID-19 are independent of direct endothelial cell infection and likely to be mediated by factors released by adjacent infected cells or circulating systemic inflammatory mediators. Our work also suggests that where viremia occurs, SARS-CoV-2 passes through the endothelium, facilitated by loss of barrier function because of local inflammation at the site of infection."

Journal • Preclinical • Cardiovascular • Ebola Virus Disease • Hematological Disorders • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • Thrombosis • ACE2 • TLR3 • TLR7

An integrated approach combining computational analyses and experimental validation deciphers the mechanism and active substance basis of Huazhuo Ningfu decoction in treating psoriasis. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "An integrated strategy was employed, combining tandem mass tag (TMT)-based quantitative proteomics and machine learning to identify critical targets in an imiquimod (IMQ)-induced mouse model of psoriasis...Our findings demonstrate that HZD alleviates psoriasis primarily by inhibiting the Notch signaling pathway and upregulating keratin 77 (KRT77), thereby normalizing keratinocyte function. The identification of nuciferine as a key multi-target constituent, along with its structural analogs, provides a pharmacological basis for HZD's efficacy and reveals promising leads for novel psoriasis therapeutics."

Journal • Dermatology • Immunology • Psoriasis • KRT7

Extramammary Paget's disease: when is enough, enough? (PubMed, Int J Womens Dermatol) - No abstract available

Journal • Dermatology • Gynecologic Cancers • Oncology • Rare Diseases • Solid Tumor • Vulvar Cancer

Genital Wart Treatment in an 18-Month-Old Child: Experience with Imiquimod. (PubMed, Indian Dermatol Online J) - No abstract available

Journal

PRIOH-1: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (clinicaltrials.gov) - P3 | N=158 | Completed | Sponsor: AiCuris Anti-infective Cures AG | Active, not recruiting ➔ Completed

Trial completion • Herpes Simplex • Infectious Disease

Imiquimod-loaded dissolvable microneedles: A novel pre-clinical immunotherapeutic approach for dermato-oncology (ESMO-IO 2025) - "These findings support further development of MN-based imiquimod delivery as part of emerging intradermal immunotherapeutic strategies in oncology. Further optimisation and in vivo evaluation are warranted to establish therapeutic efficacy and safety.Legal entity responsible for the study The authors."

Preclinical • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Squamous Cell Carcinoma

Phase Ib/II study of neoadjuvant cemiplimab plus imiquimod and laser therapy in high-risk resectable basal cell carcinoma [WITHDRAWN] (ESMO-IO 2025) - No abstract available

Clinical • P1/2 data • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology

Potential Targets and Mechanisms of Saikosaponin D in Psoriasis: A Bioinformatic and Experimental Study on Oxidative Stress. (PubMed, J Inflamm Res) - "In vivo validation employed an imiquimod-induced psoriasis mice model with Saikosaponin D (2 mg/kg/day)...Saikosaponin D suppresses psoriasis by dual-targeting STAT3/CCNB1, disrupting JAK2/STAT3 signaling and oxidative stress. This study provides new insights into the mechanism of Saikosaponin D in psoriasis, offering a promising multi-pathway therapeutic candidate."

Journal • Dermatology • Immunology • Inflammation • Psoriasis • CCNB1 • GPX4 • IL6 • SLC7A11 • TNFA

Fluidity as a key determinant of stability in PEGylated lipid nanoparticles loaded with a TLR7 agonist. (PubMed, Int J Pharm) - "To mitigate toxicity and broaden therapeutic applicability, imiquimod (IMQ), a widely used TLR7 agonist, was encapsulated in lipid-based nanocarriers (LNCs)...This system effectively reprogrammed BMDMs toward a pro-inflammatory (M1) phenotype, confirmed by gene and cytokine expression. Altogether, these results highlight the importance of formulation design and nanostructural characterization in developing nanocarrier systems that enable safer and more versatile delivery of potent immunotherapeutics such as IMQ."

IO biomarker • Journal

A Chronic Psoriasis Model Using Long-Term Imiquimod Application in IL-10-Deficient Mice: Recapitulating Skin Inflammation, Comorbidities, and Gut-Skin Axis Alterations. (PubMed, Ann Dermatol) - "The 6-week IMQ-applied IL-10 KO model may better reflect chronic and severe psoriasis with gut-related comorbidities, offering a valuable platform to investigate the gut-skin axis."

Journal • Preclinical • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Psoriasis • IL10 • IL17A • MPO • PTPRC • TNFA